Will prostate cancer respond to metabolic-directed treatment?

Chicago-Findings from systematic research being conducted by researchers at the University of California, Davis suggest that arginine deprivation may be a novel treatment in some prostate cancers.

Related Content:

Drug Therapy

Pivotal data for lumasiran in PH1 published in NEJM

Nedosiran explored in primary hyperoxaluria type 3

Enrollment completed in pivotal trial of nedosiran for hyperoxaluria